

2020

Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma

Louise Stewart

The University of Notre Dame Australia, louise.stewart@nd.edu.au

C J.R Stewart

Katrina Spilsbury

The University of Notre Dame Australia, katrina.spilsbury@nd.edu.au

P A. Cohen

S Jordan

Follow this and additional works at: https://researchonline.nd.edu.au/ihr_article



Part of the [Life Sciences Commons](#), and the [Medicine and Health Sciences Commons](#)

This article was originally published as:

Stewart, L., Stewart, C. J., Spilsbury, K., Cohen, P. A., & Jordan, S. (2020). Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma. *Gynecologic Oncology*, 156 (3), 611-615.

Original article available here:

<https://doi.org/10.1016/j.ygyno.2020.01.027>

This article is posted on ResearchOnline@ND at https://researchonline.nd.edu.au/ihr_article/34. For more information, please contact researchonline@nd.edu.au.





©2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 International license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

This is the accepted manuscript version of an article published as:

Stewart, L.M., Stewart, C.J.R., Spilsbury, K., Cohen, P.A., and Jordan, S. (2020) Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma. *Gynecologic Oncology*, 156(3), 611-615.
<https://doi.org/10.1016/j.ygyno.2020.01.027>

This article has been published in final form at [https://doi.org/ 10.1016/j.ygyno.2020.01.027](https://doi.org/10.1016/j.ygyno.2020.01.027)

1 **Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the**
2 **development of ovarian serous borderline tumor, mucinous borderline tumor and low-**
3 **grade serous carcinoma**

4

5 **Authors**

6 LM Stewart¹ Health Research and Data Analytics Hub and PHRN Centre for Data Linkage,
7 Curtin University, Bentley, Western Australia, Australia and Institute for
8 Health Research, The University of Notre Dame Australia, Fremantle,
9 Western Australia, Australia

10 CJR Stewart Department of Pathology, King Edward Memorial Hospital and School of
11 Women's and Infants' Health, The University of Western Australia, Crawley,
12 Western Australia, Australia

13 K Spilsbury Institute for Health Research, The University of Notre Dame Australia,
14 Fremantle, Western Australia, Australia and Health Research and Data
15 Analytics Hub and PHRN Centre for Data Linkage, Curtin University,
16 Bentley, Western Australia, Australia

17 PA Cohen Division of Obstetrics and Gynaecology, Faculty of Health and Medical
18 Sciences, The University of Western Australia, Crawley, Western Australia,
19 Australia; Department of Gynaecological Oncology, King Edward Memorial
20 Hospital for Women, Subiaco, Western Australia, Australia and Department of
21 Gynaecological Oncology, St John of God Hospital Bendat Family
22 Comprehensive Cancer Centre, Subiaco, Western Australia, Australia

23 S Jordan School of Public Health, The University of Queensland, Brisbane, Australia,
24 and Population Health Department, QIMR Berghofer Medical Research
25 Institute, Brisbane, Australia.

26

27 ¹ Corresponding author

28 Email louise.m.stewart@curtin.edu.au

29 Phone +61 8 9266 9455

30 Fax +61 8 92663131

31 Postal address Louise M Stewart

32 Health Research and Data Analytics Hub and PHRN Centre for Data Linkage

33 Faculty of Health Sciences

34 Curtin University

35 GPO Box U1987

36 Perth, Western Australia 6845.

37 **ABSTRACT**

38 **Objective.** Risk factors for ovarian borderline tumors and low-grade serous carcinoma
39 (LGSC) are poorly understood. The aim of this study was to examine the association between
40 infertility, pelvic inflammatory disease (PID), endometriosis, ectopic pregnancy,
41 hysterectomy, tubal ligation and parity and the risk of serous borderline tumor (SBT),
42 mucinous borderline tumor (MBT) and LGSC.

43 **Methods.** This was a population-based cohort study using linked administrative and hospital
44 data. Participants were 441,382 women born between 1945 and 1975 who had been admitted
45 to hospital in Western Australia between 1 January 1980 and 30 June 2014. We used Cox
46 regression to estimate hazard ratios (HRs).

47 **Results.** We observed an increased rate of SBT associated with infertility, PID and ectopic
48 pregnancy (HRs and 95% CIs were, respectively, 1.98 (1.20-3.26); 1.95 (1.22-3.10) and 2.44
49 (1.20-4.96)). We did not detect an association between any of the factors under study and the
50 rate of MBT. A diagnosis of PID was associated with an increased rate of LGSC (HR 2.90,
51 95% CI 1.21-6.94).

52 **Conclusions.** The association with PID supports the hypothesis that inflammatory processes
53 within the upper gynaecological tract and/or peritoneum may predispose to the development
54 of SBT and LGSC.

55 INTRODUCTION

56 Epithelial ovarian tumors are diverse in their origins, risk factors, pathology, molecular
57 biology, invasiveness and prognosis [1-5]. There are five major histotypes: high-grade serous,
58 endometrioid, clear cell, mucinous and low-grade serous. They can occur as invasive
59 carcinomas or as borderline tumors (tumors of low malignant potential).

60 Given the acknowledged diversity in tumor types, it is important that risk factors be
61 investigated separately for each subtype. For example, pelvic high-grade serous carcinoma
62 has been shown to be associated with BRCA mutations [6] and likely originates in the
63 fimbrial end of the fallopian tube [7], involving the ovary only secondarily, whereas
64 endometrioid and clear cell carcinomas have been associated with endometriosis [8].

65 Historically, a number of hypotheses have been proposed to explain the observed
66 epidemiological associations with ovarian neoplasia. The most prominent among these
67 include the incessant ovulation hypothesis [9], the gonadotrophin hypothesis [10] and the
68 inflammation hypothesis [11]. The inflammation hypothesis posits that chronic inflammation
69 results in increased cell division, the production of reactive oxygen and nitrogen species, the
70 release of prostaglandins and pro-inflammatory cytokines, all leading to the potential for
71 epigenetic alterations, errors in DNA replication, and possible tumorigenesis. Inflammatory
72 conditions that have been associated with an increased risk of ovarian cancer include
73 endometriosis, talc and asbestos exposure [12, 13] and pelvic inflammatory disease (PID).

74 PID occurs when pathogens ascend from the vagina or cervix to the upper female
75 reproductive tract. Chronic inflammation from repeated, untreated or unresolved infections
76 can lead to tubal damage, ectopic pregnancy and infertility. PID has been associated in some
77 studies with ovarian carcinoma [14], serous ovarian carcinoma [15], high-grade serous
78 ovarian carcinoma [16] and serous borderline tumors (SBT) [17]. We have previously

79 reported on the association between reproductive factors and the risk of high-grade serous
80 ovarian carcinoma [16]. The aim of the present study was to extend this work and examine
81 the association between low-grade serous ovarian carcinoma (LGSC), SBT and mucinous
82 borderline ovarian tumors (MBT), and potential risk factors including PID, infertility,
83 endometriosis, ectopic pregnancy, hysterectomy, tubal ligation and parity.

84

85 **METHODS**

86 **The study population**

87 We conducted a population-based cohort study using linked administrative and hospital data.
88 The study was set in Western Australia (WA), Australia's largest state by geographic area
89 and fourth largest by population (estimated resident population 2.6 million). Most of WA's
90 residents live in the south-west corner of the state; the remainder is sparsely populated.

91 Participants were selected from WA's Hospital Morbidity Data Collection (HMDC) [18], and
92 comprised all women, born between 1945 and 1975 inclusive, who had been admitted to a
93 WA hospital at any time between 1 January 1980 and 30 June 2014. We excluded non-
94 residents as previously described [16].

95 **Data linkage**

96 Data for this study were sourced from the WA Data Linkage System, a collection of over 35
97 different datasets maintained by the Data Linkage Branch of the WA Department of Health
98 [18]. Datasets are linked using probabilistic matching with clerical review and ongoing
99 surveillance to maximise linkage quality. We used data from the HMDC, the Midwives
100 Notification System, Birth Registrations, the WA Cancer Registry, Death Registrations and
101 the WA Electoral Roll.

102 **Exposure variables**

103 We identified diagnoses of infertility, PID, endometriosis, ectopic pregnancy and parity and
104 surgical procedures including hysterectomy (without oophorectomy or salpingectomy) and
105 tubal ligation. Medical diagnoses and surgical procedures were recorded in the HMDC, with
106 information available from 1 January 1970 onward, and coded according to contemporaneous
107 International Classification of Diseases (ICD) codes. Codes used to classify all the above
108 diagnoses and procedures, with the exception of ectopic pregnancy, have been previously
109 published [16]. Women were classified as having a tubal ectopic pregnancy if their HMDC
110 records contained a diagnosis of 633.1 or 633.9 (ICD 9) or O00.1 or O00.9 (ICD10).
111 Information on parity was derived from the Midwives Notification System for births from
112 1980 and from the WA Births Register for births 1970-1980.

113 **Outcome variables**

114 We considered three separate outcomes: diagnoses of SBT, MBT and LGCS. These were
115 recorded in the WA Cancer Registry with data available from 1982. We conducted a detailed
116 pathology review of all identified ovarian tumors, revising and reclassifying where
117 appropriate to ensure the correct classification of ovarian tumor histotypes identified in our
118 cohort [19].

119 **Bias**

120 The participants in this study were part of a dynamic population that could move in or out of
121 the state. This can lead to exposure misclassification in women who migrate into the state,
122 and loss to follow-up in women who migrate out. To minimise loss to follow-up we excluded
123 women who were overseas visitors, women who resided out of WA, women whose WA
124 Electoral Roll records showed that they had migrated out of the state, and women for whom
125 we did not have an electoral roll record showing residence in WA. Registration on the

126 Electoral Roll is compulsory for Australian citizens aged 18 years and older. We also
127 excluded women who had ovarian cancer diagnosed interstate. A flow chart of this selection
128 strategy has been previously published [16].

129 Women who migrated into the state could have given birth prior to moving into WA. We
130 were able to correctly classify parity in women who gave birth interstate or overseas and
131 subsequently gave birth in WA since the Midwives Notification System includes information
132 on previous births. However, women who had completed their family before migrating into
133 WA would have been misclassified as nulliparous since we had no record of births for these
134 women. After extensive data checking and sensitivity analyses, we found the best way to
135 address this issue was to classify parity into two categories: low parity (0-2 births) and high
136 parity (3 or more births).

137 Women were classified as having PID, endometriosis or infertility only if this was included
138 in their HMDC records. However, these conditions can be clinically occult or may be
139 diagnosed without necessarily involving hospital admission. The comparison in this study
140 therefore was not between women with and without endometriosis, for example, but rather,
141 between women with and without a hospital diagnosis of endometriosis.

142 **Data analysis**

143 We used multivariable Cox proportional hazards regression to estimate hazard ratios (HRs)
144 and 95% confidence intervals (CIs). We used age as the time scale. Follow-up was censored
145 at any ovarian tumor diagnosis, bilateral oophorectomy, oophorectomy which was not
146 specified as bilateral or unilateral, death or the censor date of 14 June 2014; whichever came
147 first. All exposure variables were included as time-varying binary variables such that each
148 individual contributed follow-up time to the unexposed category until the date of exposure
149 and thereafter contributed follow-up time to the exposed category. We examined interactions

150 between study variables and tested the proportional hazards assumption using Schoenfeld
151 residuals. We only found evidence for a violation of the assumption with PID. For this
152 reason, we also derived HRs for PID from flexible non-parametric hazard models. Statistical
153 analyses were performed using SPSS version 24 (IBM) and STATA version 14 (StataCorp,
154 College Station, Texas).

155 **Ethics**

156 The study received ethics approval from WA Department of Health Data Custodians, the WA
157 Department of Health Ethics Committee, Curtin University Human Research Ethics
158 Committee and The University of Notre Dame Human Research Ethics Committee.

159

160 **RESULTS**

161 A total of 583,488 women were admitted to hospital during the period 1980-2014 and were
162 eligible for inclusion in the study population. Following exclusion of cases as detailed in the
163 Methods, the final cohort of 441,382 women contributed 23,206,070 person-years of follow-
164 up. The median age at the end of follow-up was 52 years (interquartile range [IQR] 45-60
165 years).

166 During follow-up, 205 women were diagnosed with SBT, 138 with MBT and 41 with LGSC.
167 The median age at diagnosis of SBT was 45 years (IQR 36-52 years); MBT, 43 years (IQR
168 34-50 years) and LGSC, 49 years (IQR 40-54 years). Infertility was diagnosed in 7% of
169 women; PID in 8%, endometriosis in 8%, and 2% of women experienced an ectopic
170 pregnancy (Table 1).

171 **Serous borderline tumor (SBT)**

172 In parity-adjusted analysis, using age as the time scale, we found an increased rate of SBT
173 associated with infertility, PID and ectopic pregnancy (Table 2) for women of all ages. The
174 association with PID varied according to infertility status and so we considered four possible
175 combinations: no diagnosis of infertility and no diagnosis of PID (referent); infertility without
176 PID; PID without infertility and both PID and infertility. We found that the association
177 between PID and SBT did not satisfy the proportional hazards assumption, so we investigated
178 the association at different ages (Fig 1 and Table 3). A diagnosis of both PID and infertility in
179 women aged 35 was associated with an 8-fold increase in the rate of SBT compared to
180 women aged 35 without PID or infertility. A diagnosis of PID alone was associated with a 2-
181 fold increase in the rate of SBT while a diagnosis of infertility alone was associated with a
182 1.6-fold increase. The difference in rates between women with and without PID and
183 infertility declined with increasing age (Fig 1 and Table 3); by age 50, only a diagnosis of
184 both PID and infertility was associated with an increased rate of SBT, compared to women of
185 the same age without these conditions, although this did not reach statistical significance.
186 There was no detectable increase in the rate associated with only PID or only infertility at this
187 age (Table 3).

188 We observed a two-fold increase in the rate of SBT associated with ectopic pregnancy (HR
189 2.44; 95% CI 1.20-4.96) (Table 2). In subgroup analysis, we investigated the hypothesis that
190 the increased rate of SBT associated with ectopic pregnancy was related to prior PID. Among
191 the subset of women without a PID diagnosis, ectopic pregnancy was associated with a 2.6-
192 fold increase in the rate of SBT (HR 2.58; 95% CI 1.14-5.83). Among a smaller subset with
193 neither PID nor infertility, the HR associated with ectopic pregnancy was 2.13 (95% CI 0.94-
194 4.81).

195 **Mucinous borderline tumor (MBT)**

196 We did not detect any associations between the risk factors under study and MBT: confidence
197 intervals were wide and none of the estimates reached statistical significance. (Table 2).

198 **Low grade serous carcinoma (LGSC)**

199 We observed a three-fold increase in the rate of LGSC associated with PID. With only 41
200 cases of LGSC in the cohort, risk estimates were imprecise with wide confidence intervals.
201 Endometriosis and infertility were associated with increased hazards of LGSC, while tubal
202 ligation and high parity were inversely associated, however, none of these estimates reached
203 statistical significance (Table 2).

204

205 **DISCUSSION**

206 In this study we observed an increased risk of SBT associated with a hospital diagnosis of
207 PID. This finding is in line with previous studies, including a pooled analysis of case control
208 studies [20] and a registry-based cohort study [17]. Both of these studies identified an
209 apparent dose-response relationship, such that women with more than two episodes of PID
210 had a greater increase in risk of SBT than women with only one. Along with PID, we also
211 found an increased risk of SBT associated with hospital-diagnosed infertility and a marked
212 elevation in risk where both diagnoses were present, particularly in younger women. This
213 finding could imply a dose response effect, given that infertility as a sequela to PID is more
214 likely to occur in women with chronic or repeated infections rather than a single, promptly
215 treated infection. The heightened risk in younger women could suggest that the development
216 of SBT after PID may occur over a relatively short period of time. Alternatively, the observed
217 increased risk in younger women may be due to detection bias. Women with PID and
218 infertility may be more likely to have diagnostic imaging or laparoscopy and as a result have
219 relatively indolent tumours diagnosed, which may otherwise have escaped detection.

220 Our novel finding of an increased risk of SBT associated with ectopic pregnancy warrants
221 further investigation. PID is a known risk factor for ectopic pregnancy and it is possible that
222 the observed association with ectopic pregnancy was simply due to confounding by PID.
223 However, we also found an association between ectopic pregnancy and SBT in the absence of
224 a hospital admission for PID. The inflammatory response to an ectopic pregnancy is likely to
225 be acute and short-lived rather than chronic. If the inflammation hypothesis is correct, it is
226 unlikely that ectopic pregnancy on its own would lead to the development of SBT. Therefore,
227 we hypothesise that the observed association between ectopic pregnancy and SBT could be
228 due to PID, because many women have clinically silent infections that would not be recorded
229 as a hospital diagnosis.

230 PID leading to functional damage to the fallopian tubes and consequent ectopic pregnancy
231 may lend further support to the hypothesis of a tubal origin for serous ovarian tumors [21],
232 although currently the tubal hypothesis largely refers to high grade serous ovarian carcinoma;
233 data supporting a tubal origin of ovarian SBT and LGSC are not universally accepted.

234 We also observed an increased risk of LGSC associated with PID, a not unexpected finding
235 given that some authors have proposed that LGSC develops in a stepwise fashion from SBT
236 [22], although others have suggested this may not be true for all cases of LGSC [2].

237 Our study has a number of strengths and limitations. A particular strength of our study was
238 prior pathology review of all ovarian tumor cases, ensuring that histotypes were correctly
239 classified according to the latest criteria [19]. Other strengths include the large population-
240 based cohort and long-term follow-up, accurate recording of diagnoses and procedures in
241 hospital records thereby avoiding the possibility of recall error common in self-reported data.
242 A major limitation of our study, in common with many registry-based studies, is the
243 possibility of exposure misclassification. This can occur if a particular health condition was

244 diagnosed prior to hospital admission and not recorded in a woman's hospital records, for
245 example, if she moved into the catchment area after diagnosis, or if the condition was
246 diagnosed and treated in a primary practice rather than a hospital. This type of
247 misclassification is likely to be non-differential with respect to the outcome under study and
248 could potentially lead to an underestimation of any association.

249 In conclusion, we have found that PID appears to be associated with an increased risk of
250 developing ovarian SBT and LGSC. In a previous study we demonstrated an association
251 between PID and high grade serous ovarian carcinoma [16]. Together these results suggest
252 that chronic inflammation may play a role in the development of pelvic serous tumors.
253 Routine screening for sexually transmitted infections in young and/or high-risk populations,
254 educating women about the often-silent nature of pelvic inflammation and encouraging
255 health-care seeking behavior and early treatment, may have the potential to reduce the
256 incidence of these tumors in the future.

257

258 **ACKNOWLEDGEMENTS**

259 We gratefully acknowledge funding support from the Ovarian Cancer Research Foundation
260 (OCRF). The funding source had no role to play in study design; in the collection, analysis
261 and interpretation of data; in the writing of the report; or in the decision to submit the paper
262 for publication.

263 We would also like to thank the staff at the Western Australian Data Linkage Branch and
264 staff and custodians of the Hospital Morbidity Data Collection, the WA Cancer Registry, the
265 Midwives Notification System, Birth Registrations, Deaths Registrations and the WA
266 Electoral Roll.

267

268 **AUTHOR CONTRIBUTIONS**

269 All authors contributed to this research: to the interpretation of data, the revision of the draft
270 manuscript and approval of the final version to be published. LMS and CS contributed to the
271 conception and design and acquisition of data. LMS and KS contributed to the analysis of
272 data. LMS drafted the article.

273

274 **DECLARATION OF COMPETING INTEREST**

275 LMS received a grant from Ovarian Cancer Research Foundation during the conduct of the
276 study. PC reports grants from Ovarian Cancer Research Foundation and from Seqirus,
277 outside the submitted work. KS, CS and SJ declare they have no conflicts of interest.

278

279 **REFERENCES**

- 280 1. Gates MA, Rosner BA, Hecht JL, Tworoger SS. Risk factors for epithelial ovarian
281 cancer by histologic subtype. *Am J Epidemiol.* 2010;171(1):45-53. doi: 10.1093/aje/kwp314.
- 282 2. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with
283 emphasis on new developments and pathogenesis. *Pathology.* 2011;43(5):420-32. doi:
284 10.1097/PAT.0b013e328348a6e7.
- 285 3. Prat J. New insights into ovarian cancer pathology. *Ann Oncol.* 2012;23 Suppl
286 10:x111-7. doi: 10.1093/annonc/mds300.
- 287 4. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, et al. Ovarian
288 Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort
289 Consortium. *J Clin Oncol.* 2016;34(24):2888-98. doi: 10.1200/JCO.2016.66.8178.

- 290 5. Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, et al.
291 Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study.
292 *Int J Cancer*. 2012;131(4):938-48. doi: 10.1002/ijc.26469.
- 293 6. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic
294 oophorectomy specimens: prevalence and association with BRCA germline mutation status.
295 *Am J Surg Pathol*. 2001;25(10):1283-9. doi: 10.1097/00000478-200110000-00009.
- 296 7. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al.
297 Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal
298 Relationship. *Am J Surg Pathol*. 2007;31(2):161-9. doi:
299 10.1097/01.pas.0000213335.40358.47.
- 300 8. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al.
301 Association between endometriosis and risk of histological subtypes of ovarian cancer: a
302 pooled analysis of case-control studies. *Lancet Oncol*. 2012;13(4):385-94. doi:
303 10.1016/S1470-2045(11)70404-1.
- 304 9. Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? *Lancet*.
305 1971;2(7716):163. doi: 10.1016/s0140-6736(71)92335-x.
- 306 10. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences
307 regarding pathogenesis. *J Natl Cancer Inst*. 1983;71(4):717-21.
- 308 11. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian
309 cancer. *J Natl Cancer Inst*. 1999;91(17):1459-67. doi: 10.1093/jnci/91.17.1459.
- 310 12. Camargo MC, Stayner LT, Straif K, Reina M, Al-Alem U, Demers PA, et al.
311 Occupational exposure to asbestos and ovarian cancer: a meta-analysis. *Environ Health*
312 *Perspect*. 2011;119(9):1211-7. doi: 10.1289/ehp.1003283.
- 313 13. Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, et al.
314 Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859

315 controls. *Cancer Prev Res (Phila)*. 2013;6(8):811-21. doi: 10.1158/1940-6207.CAPR-13-
316 0037.

317 14. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian
318 cancer. *Cancer Epidemiol Biomarkers Prev*. 1995;4(5):447-51.

319 15. Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. Is Pelvic Inflammatory
320 Disease a Risk Factor for Ovarian Cancer? *Cancer Epidemiol Biomarkers Prev*.
321 2017;26(1):104-9. doi: 10.1158/1055-9965.EPI-16-0459.

322 16. Stewart LM, Spilsbury K, Jordan S, Stewart C, Holman CDJ, Powell A, et al. Risk of
323 high-grade serous ovarian cancer associated with pelvic inflammatory disease, parity and
324 breast cancer. *Cancer Epidemiol*. 2018;55:110-6. doi: 10.1016/j.canep.2018.05.011.

325 17. Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. Increased risk of
326 borderline ovarian tumors in women with a history of pelvic inflammatory disease: A
327 nationwide population-based cohort study. *Gynecol Oncol*. 2016;143(2):346-51. doi:
328 10.1016/j.ygyno.2016.08.318.

329 18. Data Linkage Western Australia. Enabling Health and Medical Research in Western
330 Australia [updated 6/17/2019; cited 11/21/2019]. Available from: [https://www.datalinkage-
331 wa.org.au/](https://www.datalinkage-wa.org.au/).

332 19. Stewart CJR, Stewart LM, Holman CDJ, Jordan S, Semmens J, Spilsbury K, et al.
333 Value of Pathology Review in a Population-based Series of Ovarian Tumors. *Int J Gynecol
334 Pathol*. 2017;36(4):377-85. doi: 10.1097/PGP.0000000000000342.

335 20. Rasmussen CB, Kjaer SK, Albieri V, Bandera EV, Doherty JA, Hogdall E, et al.
336 Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian
337 Tumors: A Pooled Analysis of 13 Case-Control Studies. *Am J Epidemiol*. 2017;185(1):8-20.
338 doi: 10.1093/aje/kww161.

- 339 21. Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-
340 grade serous neoplasms. *Histopathology*. 2013;62(1):44-58. doi: 10.1111/his.12046.
- 341 22. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma:
342 pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
343 *Adv Anat Pathol*. 2009;16(5):267-82. doi: 10.1097/PAP.0b013e3181b4fffa.

Table 1: Characteristics of the study population.

Characteristic	Study population (N=441,382) N (%)	SBT (N=205) N (%)	MBT (N=138) N (%)	LGSC (N=41) N (%)
Infertility				
No	412,523 (93.5)	188 (91.7)	132 (95.7)	>36 (>87.8)
Yes	28,859 (6.5)	17 (8.3)	6 (4.3)	<5 ² (<12.2)
PID				
No	408,047 (92.4)	185 (90.2)	130 (94.2)	35 (85.4)
Yes	33,335 (7.6)	20 (9.8)	8 (5.8)	6 (14.6)
Endometriosis				
No	406,830 (92.2)	195 (95.1)	132 (95.7)	36 (87.8)
Yes	34,552 (7.8)	10 (4.9)	6 (4.3)	5 (12.2)
Ectopic pregnancy				
No	432,442 (98.0)	197 (96.1)	>133 (>96.4)	41 (100)
Yes	8,940 (2.0)	8 (3.9)	<5 (<3.6)	0 (0)
Hysterectomy ¹				
No	393,435 (89.1)	185 (90.2)	130 (94.2)	>36 (>87.8)
Yes	47,947 (10.9)	20 (9.8)	8 (5.8)	<5 (<12.2)
Tubal ligation				
No	362,743 (82.2)	174 (84.9)	119 (86.2)	36 (87.8)
Yes	78,639 (17.8)	31 (15.1)	19 (13.8)	5 (12.2)
Parity				
Low (0-2 births)	317,605 (72.0)	162 (79.0)	111 (80.4)	35 (85.4)
High (3 or more births)	123,777 (28.0)	43 (21.0)	27 (19.6)	6 (14.6)

Abbreviations: PID, pelvic inflammatory disease; SBT, serous borderline tumor; MBT, mucinous borderline tumor; LGSC, low grade serous carcinoma

¹ Hysterectomy without salpingectomy or oophorectomy

² Subgroups numbering less than 5 are not documented to maintain participants' confidentiality.

Table 2: Hazard ratios and 95% confidence intervals from multivariable Cox models for the association between reproductive factors and the risk of serous borderline tumor (SBT) mucinous borderline tumor (MBT) and low-grade serous carcinoma (LGSC).

Characteristic	SBT		MBT		LGSC	
	HR ²	95% CI	HR	95% CI	HR	95% CI
Infertility						
No	1.00	Referent	1.00	Referent	1.00	Referent
Yes	1.98	1.20-3.26	0.98	0.43-2.23	1.68	0.52-5.47
PID						
No	1.00	Referent	1.00	Referent	1.00	Referent
Yes	1.95 ³	1.22-3.10	1.16	0.57-2.38	2.90	1.21-6.94
Endometriosis						
No	1.00	Referent	1.00	Referent	1.00	Referent
Yes	0.95	0.50-1.80	0.91	0.41-2.08	2.26	0.88-5.81
Ectopic pregnancy						
No	1.00	Referent	1.00	Referent	1.00	Referent
Yes	2.44	1.20-4.96	0.44	0.06-3.18	-	-
Hysterectomy ¹						
No	1.00	Referent	1.00	Referent	1.00	Referent
Yes	1.10	0.69-1.78	0.73	0.35-1.52	0.90	0.31-2.58
Tubal ligation						
No	1.00	Referent	1.00	Referent	1.00	Referent
Yes	0.90	0.61-1.34	0.89	0.54-1.47	0.66	0.26-1.72
Parity						
Low (0-2 births)	1.00	Referent	1.00	Referent	1.00	Referent
High (3 or more births)	0.80	0.57-1.13	0.77	0.50-1.17	0.49	0.21-1.17

Abbreviations: SBT, serous borderline tumor; MBT, mucinous borderline tumor; LGSC, low grade serous carcinoma; HR, hazard ratio; CI, confidence interval; PID, pelvic inflammatory disease.

¹Hysterectomy without salpingectomy or oophorectomy

²All HR estimates adjusted for age (age was used as the time scale) and parity.

³ The proportional hazard assumption was not satisfied for the association between PID and SBT and therefore we explored this association at different ages (Table 3 and Fig 1).

Table 3: The association between pelvic inflammatory disease (PID) and infertility and the risk of serous borderline tumor (SBT). Age-specific hazard ratios and 95% confidence intervals for the hazard of SBT associated with a diagnosis of PID and/or infertility in women of low parity.

Age	Sub-group	HR ¹	95%CI
30	No infertility, no PID	1.00	Referent
	Infertility without PID ²	1.99	0.95-4.19
	PID without infertility ³	3.60	1.70-7.60
	Both PID and infertility ⁴	17.23	5.72-51.89
35	No infertility, no PID	1.00	Referent
	Infertility without PID	1.62	0.79-3.32
	PID without infertility	2.34	1.20-4.55
	Both PID and infertility	8.42	3.58-19.79
40	No infertility, no PID	1.00	Referent
	Infertility without PID	1.36	0.66-2.77
	PID without infertility	1.59	0.83-3.07
	Both PID and infertility	4.13	1.58-10.78
45	No infertility, no PID	1.00	Referent
	Infertility without PID	1.19	0.58-2.43
	PID without infertility	1.21	0.64-2.31
	Both PID and infertility	2.56	0.89-7.36
50	No infertility, no PID	1.00	Referent
	Infertility without PID	1.09	0.53-2.23
	PID without infertility	1.03	0.54-1.96
	Both PID and infertility	2.17	0.71-6.58
55	No infertility, no PID	1.00	Referent
	Infertility without PID	1.02	0.49-2.10
	PID without infertility	0.91	0.46-1.81
	Both PID and infertility	1.93	0.51-7.30
60	No infertility, no PID	1.00	Referent
	Infertility without PID	0.95	0.46-1.99
	PID without infertility	0.81	0.38-1.71
	Both PID and infertility	1.68	0.37-7.76

Abbreviations: HR, hazard ratio; CI, confidence interval; PID, pelvic inflammatory disease.

¹HR estimates derived from a flexible non-parametric proportional hazards model with time-varying covariates, adjusted for parity and using age as the time scale.

² Women with a diagnosis of infertility in one or more of their hospital records, but no mention of PID.

³ Women with a diagnosis of PID in one or more of their hospital records, but no mention of infertility.

⁴ Women with diagnoses of both PID and infertility in one or more of their hospital records.

Figure 1: Predicted age-specific incidence rates of SBT by pelvic inflammatory disease (PID) and infertility from a flexible non-parametric proportional hazards model with time-varying covariates, adjusted for parity and using age as the time scale.

